Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Multi-Centre, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multiple Oral Dose Study to Assess the Efficacy and Tolerability of AFQ056 in Reducing L-Dopa Induced Dyskinesias in Parkinson's Patients With Severe L-Dopa Induced Dyskinesias.

Next Previous
Search
Trial Profile

A Multi-Centre, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multiple Oral Dose Study to Assess the Efficacy and Tolerability of AFQ056 in Reducing L-Dopa Induced Dyskinesias in Parkinson's Patients With Severe L-Dopa Induced Dyskinesias.

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 20 Apr 2016

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Mavoglurant (Primary)
  • Indications Drug-induced dyskinesia; Parkinson's disease
  • Focus Adverse reactions; Pharmacogenomic; Therapeutic Use

Most Recent Events

  • 03 Nov 2012 Planned number of patients (40) added as reported by European Clinical Trials Database
  • 11 Apr 2011 Results published in the Movement Disorders.
  • 13 Jun 2010 Results have been presented at the 14th International Congress of Parkinson's Disease and Movement Disorders

You need to be a logged in or subscribed to view this content Request demo (opens in a new window)

If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top